JDM Financial Group LLC Sells 31,500 Shares of Perspective Therapeutics, Inc. (NYSE:CATX)

JDM Financial Group LLC reduced its position in Perspective Therapeutics, Inc. (NYSE:CATX) by 90.0% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,500 shares of the company’s stock after selling 31,500 shares during the period. JDM Financial Group LLC’s holdings in Perspective Therapeutics were worth $47,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Geode Capital Management LLC boosted its holdings in Perspective Therapeutics by 12.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,164,204 shares of the company’s stock worth $15,546,000 after acquiring an additional 129,654 shares during the last quarter. Barclays PLC raised its stake in shares of Perspective Therapeutics by 587.9% during the 3rd quarter. Barclays PLC now owns 114,075 shares of the company’s stock worth $1,523,000 after purchasing an additional 97,493 shares during the period. XTX Topco Ltd bought a new stake in shares of Perspective Therapeutics during the 3rd quarter worth $498,000. State Street Corp raised its stake in shares of Perspective Therapeutics by 119.6% during the 3rd quarter. State Street Corp now owns 2,190,239 shares of the company’s stock worth $29,240,000 after purchasing an additional 1,192,812 shares during the period. Finally, Janus Henderson Group PLC raised its stake in shares of Perspective Therapeutics by 8.0% during the 3rd quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company’s stock worth $64,014,000 after purchasing an additional 355,685 shares during the period. 54.66% of the stock is currently owned by institutional investors.

Perspective Therapeutics Price Performance

Shares of NYSE CATX opened at $3.77 on Tuesday. Perspective Therapeutics, Inc. has a 12 month low of $2.28 and a 12 month high of $19.05. The business has a 50-day moving average of $9.56 and a 200-day moving average of $11.79.

Perspective Therapeutics (NYSE:CATX) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.21) EPS for the quarter, hitting the consensus estimate of ($0.21). Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. The company had revenue of $0.37 million during the quarter. Analysts predict that Perspective Therapeutics, Inc. will post -0.88 earnings per share for the current fiscal year.

Insider Transactions at Perspective Therapeutics

In other news, CEO Johan M. Spoor bought 14,500 shares of the business’s stock in a transaction on Monday, November 25th. The stock was acquired at an average price of $3.78 per share, with a total value of $54,810.00. Following the completion of the purchase, the chief executive officer now directly owns 152,072 shares in the company, valued at $574,832.16. This represents a 10.54 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Jonathan Robert Hunt bought 12,829 shares of the business’s stock in a transaction on Monday, November 25th. The stock was purchased at an average cost of $3.82 per share, with a total value of $49,006.78. Following the purchase, the chief financial officer now owns 48,800 shares of the company’s stock, valued at $186,416. This represents a 35.66 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 67,570 shares of company stock valued at $256,789. 3.52% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. Truist Financial assumed coverage on Perspective Therapeutics in a research note on Wednesday, September 25th. They set a “buy” rating and a $21.00 target price on the stock. Bank of America cut Perspective Therapeutics from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $24.00 to $5.00 in a research note on Monday, November 25th. UBS Group started coverage on Perspective Therapeutics in a research note on Thursday, October 24th. They issued a “buy” rating and a $20.00 price objective on the stock. Oppenheimer lowered their price objective on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a research note on Friday, November 22nd. Finally, Wedbush restated an “outperform” rating and issued a $11.00 price objective (down from $20.00) on shares of Perspective Therapeutics in a research note on Thursday, November 21st. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $15.14.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.